IceCure Medical Ltd. (ICCM)

NASDAQ: ICCM · IEX Real-Time Price · USD
1.04
-0.01 (-0.95%)
At close: Nov 29, 2022 3:56 PM
1.01
-0.03 (-2.88%)
After-hours: Nov 29, 2022 4:00 PM EST
-0.95%
Market Cap 38.77M
Revenue (ttm) 3.58M
Net Income (ttm) -15.02M
Shares Out 36.81M
EPS (ttm) -0.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 41,245
Open 1.02
Previous Close 1.05
Day's Range 0.98 - 1.05
52-Week Range 1 - 4.98
Beta 1.77
Analysts Buy
Price Target 0.01 (-99.0%)
Earnings Date Nov 29, 2022

About ICCM

IceCure Medical is a commercial stage medical device company focusing on the research, development and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. In the United States our products are approved as a “single family” known as the “IceCure Family,” which includes the IceSense3, ProSense, and MultiSense (which has not been commercialized) cryoablation systems. Cryoablation is the process by which benign and malignant tumors are ablated (destroyed) through freezing such tumors whi... [Read more]

Industry Medical Devices
Founded 2006
CEO Eyal Shamir
Employees 48
Stock Exchange NASDAQ
Ticker Symbol ICCM
Full Company Profile

Financial Performance

In 2021, ICCM's revenue was $4.14 million, an increase of 6.98% compared to the previous year's $3.87 million. Losses were -$9.90 million, 165.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for ICCM stock is "Buy." The 12-month stock price forecast is 0.01, which is a decrease of -99.04% from the latest price.

Price Target
$0.01
(-99.04% downside)
Analyst Consensus: Buy
Stock Forecasts

News

What Is Going on With IceCure Medical (ICCM) Stock Today?

IceCure Medical (NASDAQ: ICCM ) stock is taking off on Tuesday as investors react to an update for Medicare coverage of breast cancer patients. The big news investors need to know about is the Centers f...

3 weeks ago - InvestorPlace

IceCure's ProSense® Achieves Significant Milestone in Medicare Coverage of Breast Cancer Procedures

Receives assignment to a Medicare Payment Group for hospital outpatient payment Marks CMS's first payment assignment for cryoablation of breast cancer Code and preliminary payment amount for facility fe...

3 weeks ago - PRNewsWire

IceCure Launches Global #FreezeCancerNotYourLife Movement During Breast Cancer Awareness Month

ProSense® minimally invasive breast cancer procedure destroys tumors, freezing cancer in its tracks, empowering women to walk out of the procedure and back to their lives CAESAREA, Israel , Oct. 26, 202...

1 month ago - PRNewsWire

IceCure Files De Novo Classification Request with the FDA for Marketing Authorization of ProSense® with Breakthrough ...

43,000 cases estimated annually in the U.S. alone for indication in initial filing representing an estimated $80 million annual addressable market   65,000 cases estimated annually in the U.S. for broad...

1 month ago - PRNewsWire

IceCure Medical's ProSense® Cryoprobes and Introducers Receive Regulatory Approval in Brazil

Regulatory filing submitted by KTRFIOS, IceCure's distributor in Brazil ProSense Cryoablation System approval in Brazil is pending $6.6 million in expected sales during the five years following full reg...

1 month ago - PRNewsWire

IceCure Submits Regulatory Filing in Vietnam for Approval of ProSense®

Company is rapidly expanding its global regulatory and commercial reach CAESAREA, Israel , Aug. 29, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), de...

3 months ago - PRNewsWire

IceCure Medical Reports Financial Results for the First Half of 2022 and Recent Operational Highlights

Conference call scheduled for 4:30 p.m. EDT today Exclusive distribution agreement signed with Shanghai Medtronic Zhikang Medical Devices Co. Ltd.

Other symbols: MDT
3 months ago - PRNewsWire

IceCure Medical to Report H1 2022 Results and Conduct Conference Call on August 15, 2022

CAESAREA, Israel , Aug. 9, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® Syst...

3 months ago - PRNewsWire

IceCure Announces Regulatory Filing Submission for Approval of ProSense® in Canada for Indications Including Ablation...

Canadian hospitals and health care providers have expressed strong interest in ProSense® as they seek minimally invasive treatments for breast and other tumors CAESAREA, Israel , July 25, 2022 /PRNewswi...

4 months ago - PRNewsWire

Former Itamar Medical CEO & President Gilad Glick Joins IceCure Medical as a Strategic Advisor for Global Go-To-Marke...

A global medical device industry expert with a focus on market creation and fast growth, Mr. Glick has led Itamar Medical, Inc. ("Itamar Medical") as CEO, building its medical device business for a deca...

4 months ago - PRNewsWire

IceCure's ProSense® Featured at SIR 2022 Annual Meeting in Breast Cancer Cryoablation Categorical Course

Strong interest in ProSense from potential customers and distributors spurred by categorical course and Shanghai Medtronic deal CAESAREA, Israel , June 15, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NAS...

Other symbols: MDT
5 months ago - PRNewsWire

IceCure Medical, Shanghai Medtronic & Turing Medical Sign Distribution Agreement in Mainland China

Shanghai Medtronic to exclusively distribute IceSense3 cryoablation systems with a minimum purchase target of $3.5 million in the first 3 years of the contract   First IceSense3 systems to be delivered ...

Other symbols: MDT
5 months ago - PRNewsWire

IceCure Medical's ProSense® Cryoablation System Submitted for Regulatory Approval in Brazil

Regulatory filing submitted by KTRFIOS, IceCure's distributor in Brazil Filing includes breast and other cancers, benign tumors, palliative intervention, and other indications CAESAREA, Israel , June 9,...

5 months ago - PRNewsWire

IceCure Medical Reports First Quarter 2022 Financial Results and Operational Highlights

Conference call scheduled for 8:30 am ET today hosted by management with guest Dr. Richard Fine Increased commercial activity in the U.S. and globally with several new ProSense® System installations dur...

6 months ago - PRNewsWire

IceCure Medical to Report Q1 2022 Results and Conduct Conference Call May 18, 2022

CAESAREA, Israel , May 11, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® Syst...

6 months ago - PRNewsWire

IceCure Medical Presents ICE3 Breast Cancer Trial Interim Data, Hosts Cryoablation Symposium & Conducts Hands-On ProS...

CAESAREA, Israel , April 27, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® Sy...

7 months ago - PRNewsWire

IceCure Medical Announces Preliminary Unaudited 2021 Year-End Financial Results

CAESAREA, Israel, Jan. 31, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® Syst...

9 months ago - PRNewsWire

IceCure Medical CEO Issues Letter to Shareholders

CAESAREA, Israel, Jan. 5, 2022 /PRNewswire/ --  IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® Syst...

10 months ago - PRNewsWire

IceCure Medical Receives Notice of Intention to Grant a European Patent Covering Its Cryogenic Pump

CAESAREA, Israel, Dec. 20, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® Syst...

11 months ago - PRNewsWire

IceCure Medical Ltd. Closes $17 Million Underwritten Public Offering and Partial Exercise of Over-Allotment Option

CAESAREA, Israel, Dec. 13, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (the "Company" or "IceCure"), developer of minimally-invasive cryoablation technology, the ProSense® Syst...

11 months ago - PRNewsWire

IceCure Medical Ltd. Announces Pricing of $15 Million Underwritten Public Offering

CAESAREA, Israel, Dec. 9, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (the "Company" or "IceCure"), developer of minimally-invasive cryoablation technology, the ProSense® Syste...

11 months ago - PRNewsWire

IceCure Medical's Interim Results of the ICE3 Clinical Trial for Early-Stage Breast Cancer Cryoablation featured at t...

CAESAREA, Israel, Dec. 2, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® Syste...

11 months ago - PRNewsWire

IceCure Medical Announces Appointment of Merav Nir Dotan to Vice President Human Resources

CAESAREA, Israel, Nov. 29, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® Syst...

1 year ago - PRNewsWire

IceCure Medical Reports Financial Results as of and for the first Nine Months of 2021 and Recent Corporate Developments

CAESAREA, Israel, Nov. 23, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of next-generation, minimally-invasive cryoablation technology wi...

1 year ago - PRNewsWire

IceCure Medical Announces New Independent Data Published in the Journal of Cancer Therapy Showing that Percutaneous C...

CAESAREA, Israel, Nov. 1, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation minimally invasive cryoablation technology ...

1 year ago - PRNewsWire